The big three U.S. stock benchmarks were taking a breather on Friday from their run toward new record highs. The focus in markets still was very much on the firehose of policy initiatives from ...
The U.S. stock market’s so-called fear gauge was on pace to potentially end at its lowest level of the year as investors looked to close out the first week of trading since President Donald Trump ...
The U.S. stock market was slipping midday Friday, but all three major indexes remained on track for back-to-back weekly gains. The Dow Jones Industrial Average was down 72 points in midday trading, or ...
American Express shares fell about 3% Friday after the company reported earnings and gave an outlook that disappointed some ...
The U.S. dollar is testing its “support” zone after falling this week, according to Fairlead Strategies. The U.S. Dollar Index was down 0.3% on Friday morning at 107.70, trading around its 50-day ...
The U.S. stock market closed higher Thursday, bringing the year-to-date gain of the SPDR S&P 500 ETF Trust SPY to 4%. The S&P 500 climbed 0.5% on Thursday to a record high, lifted by a broad rally ...
The NASDAQ Composite Index is up 44.34 points or 0.22% today to 20053.68 --Largest four-day percentage gain since Tuesday, Jan. 21, 2025 --Longest winning streak since Wednesday, Dec. 4, 2024, when ...
Complete New Zealand Dollar/ US Dollar Dec 2025 futures overview by Barron's. View the KZXIZ25 futures and commodity market news with real-time price data for better-informed trading.
American Airlines Group reported solid earnings growth that topped estimates, but guidance for Q1 2025 disappointed Wall Street.
Complete Australian Dollar/Japanese Yen Dec 2025 futures overview by Barron's. View the YAZ25 futures and commodity market news with real-time price data for better-informed trading.
U.S. stocks finished higher on Wednesday after a slew of robust corporate earnings and President Donald Trump's new initiative on artificial intelligence pushed Wall Street closer to record territory.
Cantor Fitzgerald analyst Ross Osborn increased the 12-month price target on Sanara MedTech shares to $46 from $44, while maintaining an Overweight rating. The adjustment follows Sanara's announcement ...